Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: A multicenter, multicohort clinical trial (ALTER-G-001)

被引：1
|
作者：
Liu, Jing
Wu, Junwei
Zhu, Liangjun
Yan, Jun
Mao, Yong
Tang, Xinyu
Zhu, Lingjun
Jiang, Hong
Wei, Xiaowei
Shangguan, Chengfang
Xi, Wenqi
Shi, Yan
Shi, Min
Zhou, Chenfei
Yang, Hui
Zhang, Jun
机构：
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Oncol, Shanghai, Peoples R China
[2] Jiansu Canc Hosp, Dept Oncol, Nanjing, Peoples R China
[3] Shanghai Univ Med & Hlth Sci, Jiading Cental Hosp, Dept Oncol, Shanghai, Peoples R China
[4] Jiannan Univ, Affiliated Hosp, Dept Oncol, Wuxi, Jiangsu, Peoples R China
[5] Ruijin Hosp, Wuxi Branch, Dept Oncol, Wuxi, Jiangsu, Peoples R China
[6] Jiangsu Prov Hosp, Dept Oncol, Nanjing, Peoples R China
[7] Tongji Univ, Tongji Hosp, Dept Oncol, Shanghai, Peoples R China
[8] Nanjing First Hosp, Dept Oncol, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.TPS229
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS229
引用
收藏
页数：3
相关论文
共 50 条
  • [31] ALTER-UC-001: Phase II trial of anlotinib plus everolimus as first-line treatment for advanced non-clear cell renal cell carcinoma
    Zhang, Hailiang
    Ye, Ding-Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] A multicenter, randomized, phase II trial of anlotinib plus docetaxel versus docetaxel in EGFR-negative NSCLC patients after progression on first-line platinum-base chemotherapy: ALTER-L018.
    Wu, Lin
    Wu, Zhijun
    Xiao, Zemin
    Ma, Zhongsha
    Weng, Jie
    Chen, Yanhua
    Cao, Yongqing
    Cao, Peiguo
    Xiao, Maoliang
    Zhang, Hui
    Duan, Huaxin
    Wang, Qianzhi
    Li, Jia
    Xu, Yan
    Pu, Xingxiang
    Li, Kang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] Updated results from ALTER-C001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC.
    Yan, Jin
    Han, Yunwei
    Zhang, Li
    Jin, Yongdong
    Sun, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 137 - 137
  • [34] Update results from ALTER-C-001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC: A single arm, multi-center, phase II clinical trial
    Jin, Y.
    Han, Y.
    Zhang, L.
    Jin, Y.
    Sun, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S546 - S547
  • [35] Early tumor shrinkage as a predictor of favorable outcomes in patients with unresectable metastatic colorectal cancer treated with first-line chemotherapy plus bevacizumab
    Behourah, Z.
    Ameziane, N.
    Aida, M.
    Messaoud, M. Ahed
    Bousahba, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S178 - S178
  • [36] Bevacizumab plus chemotherapy versus chemotherapy alone as first-line treatment for patients with RAS mutant unresectable colorectal liver-limited metastases: A single center randomized control trial
    Xu, J.
    Liu, T.
    Tang, W.
    Chang, W.
    Feng, Q.
    Wei, Y.
    Ren, L.
    Ye, Q.
    Cui, Y.
    He, G.
    Liu, T.
    Zhu, D.
    Ji, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [37] Survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasis.
    Tsai, Hsiang-Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 56 - 56
  • [38] Impact on survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasis
    Chen, Yen-Cheng
    Chang, Tsung-Kun
    Su, Wei-Chih
    Yeh, Yung-Sung
    Chen, Po-Jung
    Huang, Peng-Jen
    Yang, Po-Hsiang
    Tsai, Hsiang-Lin
    Wang, Jaw-Yuan
    Huang, Ching-Wen
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2024, 39 (01)
  • [39] Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial
    Chen, Xinni
    Qin, Shukui
    Gu, Shanzhi
    Ren, Zhenggang
    Chen, Zhendong
    Xiong, Jianping
    Liu, Ying
    Meng, Zhiqiang
    Zhang, Xiao
    Wang, Linna
    Zhang, Xiaojing
    Zou, Jianjun
    INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (11) : 1944 - 1954
  • [40] Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial
    Szlosarek, Peter W.
    Creelan, Benjamin C.
    Sarkodie, Thomas
    Nolan, Luke
    Taylor, Paul
    Olevsky, Olga
    Grosso, Federica
    Cortinovis, Diego
    Chitnis, Meenali
    Roy, Amy
    Gilligan, David
    Kindler, Hedy
    Papadatos-Pastos, Dionysis
    Ceresoli, Giovanni L.
    Mansfield, Aaron S.
    Tsao, Anne
    O'Byrne, Kenneth J.
    Nowak, Anna K.
    Steele, Jeremy
    Sheaff, Michael
    Shiu, Chiung-Fang
    Kuo, Chih-Ling
    Johnston, Amanda
    Bomalaski, John
    Zauderer, Marjorie G.
    Fennell, Dean A.
    JAMA ONCOLOGY, 2024, 10 (04) : 475 - 483
12345